Navigation Links
Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
Date:5/28/2009

HORSHAM, Pa., May 28 /PRNewswire/ -- Centocor Ortho Biotech Products, L.P. today announced that data related to several compounds will be presented at the 45th American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fla., from May 29 to June 2, 2009. The studies were sponsored by Centocor Ortho Biotech Products, L.P. or its research partner, Ortho Biotech Oncology Research and Development, a unit of Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

"We are pleased that ASCO has accepted these data for presentation at their annual meeting," said Thomas Schaible, Vice President, Medical Affairs, Centocor Ortho Biotech. "Through our ongoing investigation of key clinical compounds, Centocor Ortho Biotech is committed to advancing the understanding of the therapeutic options it offers to patients fighting cancer."

Data from the following studies have been selected for presentation and posters:

  • Relationship of rapid M protein reduction to outcomes in a trial of pegylated liposomal doxorubicin (PLD) plus bortezomib (B) versus B alone in previously treated multiple myeloma (MM) (Abstract 8591) General Poster Session, Saturday May 30, 8:00 am to 12:00 pm, Level 2, West Hall C

Authors: J. J. Shah, A. Londhe, K. C. Lantz, C. Lowery, R. Z. Orlowski; University of Texas M. D. Anderson Cancer Center, Houston, TX; Centocor Ortho Biotech Services LLC, Horsham, PA

  • Correlation of CA-125 and RECIST evaluation in recurrent ovarian cancer (ROC): Results from a randomized phase III study of trabectedin (T) with pegylated liposomal doxorubicin (PLD) versus PLD alone (Abstract 5550)

General Poster Session, Sunday May 31, 2:00 pm to 6:00 pm, Level 2, West Hall C

Authors: T.
'/>"/>

SOURCE Centocor Ortho Biotech Products, L.P.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
2. Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
3. Centocor/Janssen-Cilags Ustekinumab Will Become the Gold Standard for Psoriasis By 2011
4. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
5. Ortho Biotech, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product
6. GeneNews provides Centocor access to its osteoarthritis program
7. Baseline Research Indicates High Interest in Centocor-Ortho Biotechs SIMPONI(R)
8. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients
9. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
10. New Orthopedic Surgical Robotics Company Opens Its Doors; Files with the FDA for Clearance of Its Flagship Product
11. Innovative Neurotronics, a Subsidiary of Hanger Orthopedic Group, Earns the 2007 da Vinci Award for the WalkAide System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... June 19, 2013 BioConvergence team ... speaking faculty at 2013’s BioLogistics Summit in San ... coordinated by Cold Chain IQ and IQPC, addressed ... “complexity” is, in part, attributed to current trends ... “Implicit within these trends is an increase in ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Express Diagnostics ... tests, today announced that it has received Class III ... and sell its DrugCheck® NxStep Onsite Drug Screen ... of the rapid screening device in near-patient settings, such ... Screen Cup received Health Canada Class III approval for ...
(Date:6/18/2013)... China Cord Blood Corporation (NYSE: ... of cord blood collection, laboratory testing, hematopoietic stem cell ... preliminary unaudited financial results for the fourth quarter and ... 2013. Fourth Quarter of Fiscal 2013 ... fiscal 2013 increased by 33.3% to RMB133.0 million ($21.4 ...
(Date:6/18/2013)... Philadelphia, PA (PRWEB) June 18, 2013 ... fiber-optic Ball Lenses engineered of synthetic Sapphire and Glass ... stock sizes from Swiss Jewel Company , of ... performance by expanding and collimating the light beams without ... extreme optical clarity and natural durability (9 mohs) make ...
Breaking Biology Technology:BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 2China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 4China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 5China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 6China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 7China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 8China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 9China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 10China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 11China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 12China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 13Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors 2
... /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading ... that effective on March 16, 2009 the exercise term ... the holder to purchase one Class A common share ... extended from March 23, 2009 to December 31, 2009. ...
... Food Processing, Industry,VANCOUVER, March 2 ... "the Company") today announced that it has completed ... dehydration equipment to CAL-SAN Enterprises, Ltd. of Richmond, ... With this sale, EnWave has proven that it ...
... Part of "In the Zone for UC" Campaign, Centocor ... & Colitis Foundation of America for Each Point Pisani ... Centocor Ortho Biotech Inc. announced today a partnership with ... ulcerative colitis (UC) and funding to support continued education ...
Cached Biology Technology:BioMS Medical warrant extension 2EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 2EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 3EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 4Pro Hockey Player Fernando Pisani Looks to Shoot and Score Against Ulcerative Colitis 2Pro Hockey Player Fernando Pisani Looks to Shoot and Score Against Ulcerative Colitis 3Pro Hockey Player Fernando Pisani Looks to Shoot and Score Against Ulcerative Colitis 4
(Date:6/18/2013)... Kingdom, the Energy Department,s National Renewable Energy Laboratory ... published a paper describing a novel cellulose-degrading enzyme ... , commonly known as the gribble. , ... relatively unique ability to produce their own enzymes ... the biomass they eat. New biomass-degrading enzymes from ...
(Date:6/18/2013)... awarded $12.7 million to match nine academic research ... to explore new treatments for patients in eight ... and schizophrenia. The collaborative pilot initiative, called Discovering ... by the National Center for Advancing Translational Sciences ... , The process of developing a new therapeutic ...
(Date:6/18/2013)... a chemical modification of DNA and this modification ... DNA sequence. Until now, scientists believed that this ... genes. Today, a team of researchers from the ... Dermitzakis, Louis-Jeantet Professor at the Faculty of Medicine, ... and that DNA methylation may play both a ...
Breaking Biology News(10 mins):Novel enzyme from tiny gribble could prove a boon for biofuels research 2NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4The secret of DNA methylation 2
... Understanding the tens of thousands of proteins that compose the ... century, and research efforts to date have already enabled major ... potential avenues have been blocked by lack of information about ... bulk of these so far enigmatic proteins may now be ...
... Displays, Without Sacrificing Display Viewing QualityTHE WOODLANDS, Texas, ... UNXL), the developer of a unique new thin ... announced the availability of test samples for customers. ... to produce a transparent protective cover film that ...
... University of Pennsylvania has completed a research study begun in ... the northwest Atlantic Ocean around Mount Desert Island, Me., has ... during less than a century, providing a clear illustration of ... is published in the current issue of the Proceedings ...
Cached Biology News:New high-throughput screening technique makes probing puzzling proteins possible 2New high-throughput screening technique makes probing puzzling proteins possible 3New high-throughput screening technique makes probing puzzling proteins possible 4New high-throughput screening technique makes probing puzzling proteins possible 5UniPixel Announces Availability of Opcuity(TM) Finger Print Resistant Film Test Samples 2UniPixel Announces Availability of Opcuity(TM) Finger Print Resistant Film Test Samples 3Penn biologists demonstrate that size matters... in snail shells 2Penn biologists demonstrate that size matters... in snail shells 3
... is designed to allow neomycin/kanamycin selection ... The loxP-PGK-gb2-neo-loxP template encodes the neomycin/kanamycin ... promoter (gb2) for expression of kanamycin ... promoter (PGK) for expression of neomycin ...
These are replacement caps for No. CLS6980 5mm PYREX NMR tubes. Proper method to remove caps is to slice them from the tube. Caps come in eight assorted/mixed colors. Packed in bags of 100....
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ID ...
Preparation TW--Compatibility: Push-on end cap seals suitable up to 70 C only -Hybridization Tube for Model HB-1D -Comp Dim: 200 80 mm -Material: borosilicate glass -Mfr Desig: Techne FHB-12...
Biology Products: